Collegium Reports First Quarter 2024 Financial Results
May 09, 2024 16:02 ET
|
Collegium Pharmaceutical, Inc.
– Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net...
PDF Solutions® Reports First Quarter 2024 Results
May 09, 2024 16:02 ET
|
PDF Solutions, Inc.
SANTA CLARA, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- PDF Solutions, Inc. (Nasdaq: PDFS), a leading provider of comprehensive data solutions for the semiconductor ecosystem, today announced...
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024 16:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
May 09, 2024 16:01 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company dedicated to the global development and...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
May 09, 2024 16:01 ET
|
MacroGenics, Inc.
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09,...
Research Frontiers Reports First Quarter 2024 Financial Results and Will Host a Conference Call at 5:30p.m. Today
May 09, 2024 16:01 ET
|
Research Frontiers Incorporated
WOODBURY, N.Y., May 09, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its first quarter of 2024. Management will host a conference call today at...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
May 09, 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
May 09, 2024 16:01 ET
|
Ventyx Biosciences, Inc.
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk...
Collegium Announces CEO Transition
May 09, 2024 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has...
Progyny, Inc. Announces First Quarter 2024 Results
May 09, 2024 16:01 ET
|
Progyny
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a transformative fertility, family building and women's health benefits solution, today...